Literature DB >> 17183192

Glucocorticoids down-regulate lipopolysaccharide-induced de novo production of neurotensin mRNA in the rat hypothalamic, paraventricular, corticotrophin-releasing hormone neurons.

Elodie Loum-Ribot1, Pierrette Lafon, Michel Chaigniau, Gerard Tramu, Marc Corio.   

Abstract

OBJECTIVE: Intraperitoneal injection of the endotoxin lipopolysaccharide (LPS) produces inflammation accompanied by activation of the immune system and the secretion of cytokines. Cytokines stimulate the hypothalamo-pituitary-adrenal (HPA) axis to release the anti-inflammatory corticosterone which controls its own production by acting on the HPA axis. Upstream in the HPA axis are neuroendocrine corticotrophin-releasing hormone (CRH) neurons located in the paraventricular nucleus (PVN), whose multipeptidergic phenotype changes during inflammation: while CRH mRNA is up-regulated in these conditions, neurotensin (NT) mRNA expression is induced de novo. The negative feedback control of glucocorticoids on CRH production is well documented; however, their action on NT production in the PVN of the hypothalamus is poorly documented. The aim of this study was to determine if glucocorticoids modulate the de novo production of NT during inflammation.
METHODS: Using quantitative in situ hybridization histochemistry, we examined whether the absence (adrenalectomy) or excess (corticosterone implants) of glucocorticoids modulate de novo production of NT mRNA in the PVN during inflammation induced by LPS treatment.
RESULTS: A relatively low dose of LPS (50 microg/kg) that is not efficient to induce NT mRNA production in the PVN becomes efficient after adrenalectomy. Moreover, corticosterone excess reduces LPS-induced production of NT mRNA in the PVN.
CONCLUSION: Glucocorticoids exert a negative control on NT mRNA production in the PVN of the hypothalamus, and this effect requires that NT mRNA production be triggered, such as during inflammation. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17183192     DOI: 10.1159/000098130

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  6 in total

Review 1.  The Immune System and the Role of Inflammation in Perinatal Depression.

Authors:  Philippe Leff-Gelman; Ismael Mancilla-Herrera; Mónica Flores-Ramos; Carlos Cruz-Fuentes; Juan Pablo Reyes-Grajeda; María Del Pilar García-Cuétara; Marielle Danitza Bugnot-Pérez; David Ellioth Pulido-Ascencio
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

2.  In vivo Angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland.

Authors:  Enrique Sánchez-Lemus; Julius Benicky; Jaroslav Pavel; Juan M Saavedra
Journal:  Brain Behav Immun       Date:  2009-05-07       Impact factor: 7.217

3.  Mitogen-activated protein kinase contributes to lipopolysaccharide-induced activation of corticotropin-releasing hormone synthesizing neurons in the hypothalamic paraventricular nucleus.

Authors:  Praful S Singru; Edith Sánchez; Runa Acharya; Csaba Fekete; Ronald M Lechan
Journal:  Endocrinology       Date:  2008-01-10       Impact factor: 4.736

4.  Role of TLR4 in the Modulation of Central Amygdala GABA Transmission by CRF Following Restraint Stress.

Authors:  F P Varodayan; S Khom; R R Patel; M Q Steinman; D M Hedges; C S Oleata; G E Homanics; M Roberto; M Bajo
Journal:  Alcohol Alcohol       Date:  2018-11-01       Impact factor: 2.826

Review 5.  Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder.

Authors:  JiaJun Liu; Femke Buisman-Pijlman; Mark R Hutchinson
Journal:  Front Neurosci       Date:  2014-09-30       Impact factor: 4.677

6.  Interaction Mechanisms Between Major Depressive Disorder and Non-alcoholic Fatty Liver Disease.

Authors:  Qi Shao; Yiping Wu; Jing Ji; Tian Xu; Qiaoyu Yu; Chongyang Ma; Xuejing Liao; Fafeng Cheng; Xueqian Wang
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.